ArticleScientific reports2025
Integrative bioinformatics analysis identifies METTL1 as a regulator of immune infiltration and prognosis in breast cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- MYC promotes myocardial fibrosis via METTL1-mediated m7G modification of HILPDA.Biology direct · 2026Article
- The methyltransferase-like proteins as core regulators of nucleic acid modifications and post-translation modification of proteins in disease pathogenesis and therapeutic implications.Biomarker research · 2025Review
- The emerging roles of METTL1-mediated tRNA mFrontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
To explore the role of Methyltransferase-like 1 (METTL1) in the prognosis, diagnosis, and immune infiltration of Breast invasive carcinoma (BRCA), transcriptome data of BRCA from The Cancer Genome Atlas (TCGA) database were analyzed. Then, the METTL1 expression in normal and cancer tissues was compared using the DESeq2 package. Next, the diagnostic and prognostic value of METTL1 was evaluated using receiver operating characteristic curves and survival analysis, respectively. Co-expressed genes and differentially expressed genes related to METTL1 were identified using Pearson correlation and Wilcoxon tests, with overlapping genes subjected to protein-protein interaction network construction to identify hub genes via degree algorithm. After that, immune infiltration analyses were performed using CIBERSORT and xCELL algorithms. METTL1 expression was significantly higher in BRCA tissues compared to normal tissues, with significant diagnostic value. Furthermore, BRCA patients with low METTL1 expression showed better 5-year overall survival and disease specific survival than those with high METTL1 expression. A total of 1829 differentially expressed genes and 236 co-expressed genes were identified, with five hub genes selected. These genes, along with METTL1, were positively associated with immunosuppressive cell types, such as regulatory T cells and follicular helper T cells, suggesting their role in shaping an immunosuppressive tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.